for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cocrystal Pharma Inc

COCP.OQ

Latest Trade

0.51USD

Change

0.01(+2.55%)

Volume

10,891

Today's Range

0.46

 - 

0.52

52 Week Range

0.42

 - 

5.27

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.50
Open
0.50
Volume
10,891
3M AVG Volume
1.30
Today's High
0.52
Today's Low
0.46
52 Week High
5.27
52 Week Low
0.42
Shares Out (MIL)
31.62
Market Cap (MIL)
15.99
Forward P/E
-2.39
Dividend (Yield %)
--

Latest Developments

More

Cocrystal Pharma Reports Qtrly Loss Per Share $0.06

Cocrystal Pharma Presents Positive Data From U.S. Phase 2a Study Of CC-31244 Demonstrating Ability To Identify Patients More Likely To Respond To Ultrashort Treatment Of HCV

Cocrystal Pharma Expects To Grant Underwriters Option To Purchase Up To Additional 15% Common Shares

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cocrystal Pharma Inc

Cocrystal Pharma, Inc., is a clinical stage biotechnology company. The Company focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis C, influenza and norovirus. The Company uses computational methods to screen and design product candidates using its cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a novel PB2 inhibitor for the treatment of influenza infection. The Company is also focused on identifying and developing nucleoside and non-nucleoside polymerase inhibitors for the treatment of Norovirus infections.

Industry

Biotechnology & Drugs

Contact Info

19805 N Creek Pkwy

+1.786.4591831

https://www.cocrystalpharma.com/

Executive Leadership

Gary L. Wilcox

Chairman of the Board, Chief Executive Officer

Sam Lee

President

James J. Martin

Chief Financial Officer

David S. Block

Director

Todd R. Brady

Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
EPS (USD)

2018

0.170

2019(E)

-0.280
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.82
Price To Book (MRQ)
0.20
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.31
LT Debt To Equity (MRQ)
0.03
Return on Investment (TTM)
-45.08
Return on Equity (TTM)
-44.42

Latest News

Latest News

BRIEF-Cocrystal Pharma Prices $8,000,000 Common Stock Offering

* COCRYSTAL PHARMA, INC., PRICES $8,000,000 COMMON STOCK OFFERING

BRIEF-Cocrystal Pharma Provides Corporate Overview

* COCRYSTAL PHARMA REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE OVERVIEW AND BUSINESS OUTLOOK

BRIEF-Cocrystal Pharma Files For Non Timely 10-K

* COCRYSTAL PHARMA INC FILES FOR NON TIMELY 10-K - SEC FILING Source text - http://bit.ly/2FMME8d Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up